Presentation is loading. Please wait.

Presentation is loading. Please wait.

Relationship between a) forced expiratory flow at 25–75% of forced vital capacity (FVC) (FEF25–75%) and b) forced expiratory flow at 75% of FVC (FEF75%)

Published byΠιλάτος Βιτάλης Modified over 5 years ago

Similar presentations

Presentation on theme: "Relationship between a) forced expiratory flow at 25–75% of forced vital capacity (FVC) (FEF25–75%) and b) forced expiratory flow at 75% of FVC (FEF75%)"— Presentation transcript:

1 Relationship between a) forced expiratory flow at 25–75% of forced vital capacity (FVC) (FEF25–75%) and b) forced expiratory flow at 75% of FVC (FEF75%) and forced expiratory volume in 1 s (FEV1), both standardised for the FVC. Note that the y-axis is log-t... Relationship between a) forced expiratory flow at 25–75% of forced vital capacity (FVC) (FEF25–75%) and b) forced expiratory flow at 75% of FVC (FEF75%) and forced expiratory volume in 1 s (FEV1), both standardised for the FVC. Note that the y-axis is log-transformed. Philip H. Quanjer et al. Eur Respir J 2014;43: ©2014 by European Respiratory Society

Download ppt "Relationship between a) forced expiratory flow at 25–75% of forced vital capacity (FVC) (FEF25–75%) and b) forced expiratory flow at 75% of FVC (FEF75%)"

Similar presentations

Effects of respiratory rate and tidal volume on evaporative loss at constant intrapulmonary perfluorocarbon volume (10 mL·kg−1) and positive end-expiratory.

Effects of respiratory rate and tidal volume on evaporative loss at constant intrapulmonary perfluorocarbon volume (10 mL·kg−1) and positive end-expiratory.
Pulmonary response in sarcoidosis

Pulmonary response in sarcoidosis
Examples of computerised incentives used in spirometry

Examples of computerised incentives used in spirometry
Least squares (LS) mean change from baseline (95% CI) in trough forced expiratory volume in 1 s (FEV1) according to chronic obstructive pulmonary disease.

Least squares (LS) mean change from baseline (95% CI) in trough forced expiratory volume in 1 s (FEV1) according to chronic obstructive pulmonary disease.
William G. Flight, Jonathan Shaw, Susan Johnson, A

William G. Flight, Jonathan Shaw, Susan Johnson, A
Summary findings regarding the efficacy/safety profile across xanthines in chronic obstructive pulmonary disease patients. a) Combined plot of the change.

Summary findings regarding the efficacy/safety profile across xanthines in chronic obstructive pulmonary disease patients. a) Combined plot of the change.
Relationship between the change in a) ventilatory and b) cerebrovascular responses in older healthy subjects (Older) and chronic obstructive pulmonary.

Relationship between the change in a) ventilatory and b) cerebrovascular responses in older healthy subjects (Older) and chronic obstructive pulmonary.
Change from baseline in trough forced expiratory volume in 1 s (FEV1) (per-protocol population). Change from baseline in trough forced expiratory volume.

Change from baseline in trough forced expiratory volume in 1 s (FEV1) (per-protocol population). Change from baseline in trough forced expiratory volume.
Distribution of forced expiratory volume in 1 s (FEV1) relative to Global Lung Function Initiative reference values (GLI2012) [10] expressed as FEV1 %

Distribution of forced expiratory volume in 1 s (FEV1) relative to Global Lung Function Initiative reference values (GLI2012) [10] expressed as FEV1 %
Chronic Obstructive Pulmonary Disease: An Evidence-Based Approach to Treatment With a Focus on Anticholinergic Bronchodilation  Nicholas J. Gross, MD,

Chronic Obstructive Pulmonary Disease: An Evidence-Based Approach to Treatment With a Focus on Anticholinergic Bronchodilation  Nicholas J. Gross, MD,
Forced expiratory volume in 1 s (FEV1) results in the RECOVER trial.

Forced expiratory volume in 1 s (FEV1) results in the RECOVER trial.
The values for the provoking dose of mannitol to cause a 15% decrease (PD15) in forced expiratory volume in 1 s (FEV1) showing the different levels of.

The values for the provoking dose of mannitol to cause a 15% decrease (PD15) in forced expiratory volume in 1 s (FEV1) showing the different levels of.
The relationship between body mass index (BMI) and per cent predicted forced expiratory volume in 1 s (FEV1) (A) and per cent predicted forced vital capacity.

The relationship between body mass index (BMI) and per cent predicted forced expiratory volume in 1 s (FEV1) (A) and per cent predicted forced vital capacity.
Respiratory Function Changes in a Wilderness Multisport Endurance Competition: A Prospective Case Study  Ian R. Rogers, MBBS, FACEM, Dale Speedy, MBChB,

Respiratory Function Changes in a Wilderness Multisport Endurance Competition: A Prospective Case Study  Ian R. Rogers, MBBS, FACEM, Dale Speedy, MBChB,
Immunostaining for lipid peroxidation product 4-hydroxy-2-nonenal (4-HNE) adduct in the lungs of smokers with and without chronic obstructive pulmonary.

Immunostaining for lipid peroxidation product 4-hydroxy-2-nonenal (4-HNE) adduct in the lungs of smokers with and without chronic obstructive pulmonary.
A) Exhaled nitric oxide fraction (FeNO) before and after 9 weeks of treatment; b) percentage change in forced expiratory volume in 1 s (FEV1) following.

A) Exhaled nitric oxide fraction (FeNO) before and after 9 weeks of treatment; b) percentage change in forced expiratory volume in 1 s (FEV1) following.
A) Forced expiratory volume in 1 s (FEV1)/forced vital capacity (FVC) ratio as a function of age showing individuals with FEV1/FVC ratio less than the.

A) Forced expiratory volume in 1 s (FEV1)/forced vital capacity (FVC) ratio as a function of age showing individuals with FEV1/FVC ratio less than the.
Change from baseline following beclomethasone/formoterol and placebo in a) platelet–monocyte aggregate formation, b) P-selectin expression and c) platelet.

Change from baseline following beclomethasone/formoterol and placebo in a) platelet–monocyte aggregate formation, b) P-selectin expression and c) platelet.
A) In the presence of Aspergillus fumigatus, local IgA and IgG levels to A. fumigatus are significantly elevated; *: p

A) In the presence of Aspergillus fumigatus, local IgA and IgG levels to A. fumigatus are significantly elevated; *: p
A) Peak forced expiratory volume in 1 s within 3 h post-dosing (peak FEV10–3h) response following once-daily tiotropium Respimat add-on to medium-dose.

A) Peak forced expiratory volume in 1 s within 3 h post-dosing (peak FEV10–3h) response following once-daily tiotropium Respimat add-on to medium-dose.

Similar presentations

Ads by Google